This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Sunshine Lake Pharma Co., Ltd.. Active years: 2017.
Company Filing History:
Years Active: 2017
Title: Shun Bai: Innovator in CDK Inhibitors
Introduction
Shun Bai is a prominent inventor based in Dongguan, China. He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds that serve as cyclin-dependent kinase (CDK) inhibitors. His work focuses on addressing critical health issues related to inflammation and cell proliferation diseases.
Latest Patents
Shun Bai holds a patent for "2-amino-pyrido[2,3-D]pyrimidin-7(8H)-one derivatives as CDK inhibitors and uses thereof." This invention provides novel compounds that act as small-molecule inhibitors of CDK, specifically targeting CDK 4 and CDK 6. The compounds developed by Bai have potential applications in treating various diseases associated with inflammation and abnormal cell growth. He has 1 patent to his name.
Career Highlights
Shun Bai is currently associated with Sunshine Lake Pharma Co., Ltd., where he continues to innovate and develop new therapeutic solutions. His expertise in medicinal chemistry has positioned him as a key player in the pharmaceutical industry, contributing to advancements in drug development.
Collaborations
Shun Bai has collaborated with notable colleagues, including Bing Liu and Yingjun Zhang. These partnerships have fostered a collaborative environment that enhances research and development efforts within the company.
Conclusion
Shun Bai's contributions to the field of CDK inhibitors exemplify the impact of innovative research in medicine. His work not only advances scientific knowledge but also holds promise for improving patient outcomes in the treatment of serious health conditions.